These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34514806)

  • 41. Validation of the VTE-BLEED score's long-term performance for major bleeding in patients with venous thromboembolisms: From the COMMAND VTE registry.
    Nishimoto Y; Yamashita Y; Morimoto T; Saga S; Amano H; Takase T; Hiramori S; Kim K; Oi M; Akao M; Kobayashi Y; Yoshikawa Y; Shiomi H; Kato T; Makiyama T; Ono K; Sato Y; Kimura T;
    J Thromb Haemost; 2020 Mar; 18(3):624-632. PubMed ID: 31785073
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review.
    Klok FA; Kooiman J; Huisman MV; Konstantinides S; Lankeit M
    Eur Respir J; 2015 Jan; 45(1):201-10. PubMed ID: 25102964
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
    Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
    Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
    Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
    Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients.
    Mearns ES; Kohn CG; Song JS; Hawthorne J; Meng J; White CM; Raut MK; Schein JR; Coleman CI
    Thromb Res; 2014 Aug; 134(2):310-9. PubMed ID: 24935672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Gao X; Cai X; Yang Y; Zhou Y; Zhu W
    Front Cardiovasc Med; 2021; 8():757087. PubMed ID: 34881309
    [No Abstract]   [Full Text] [Related]  

  • 47. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous Thromboembolism.
    Scharrer S; Primas C; Eichinger S; Tonko S; Kutschera M; Koch R; Blesl A; Reinisch W; Mayer A; Haas T; Feichtenschlager T; Fuchssteiner H; Steiner P; Ludwiczek O; Platzer R; Miehsler W; Tillinger W; Apostol S; Schmid A; Schweiger K; Vogelsang H; Dejaco C; Herkner H; Novacek G;
    Inflamm Bowel Dis; 2021 Oct; 27(11):1773-1783. PubMed ID: 33386735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper.
    Gorog DA; Gue YX; Chao TF; Fauchier L; Ferreiro JL; Huber K; Konstantinidis SV; Lane DA; Marin F; Oldgren J; Potpara T; Roldan V; Rubboli A; Sibbing D; Tse HF; Vilahur G; Lip GYH
    Thromb Haemost; 2022 Oct; 122(10):1625-1652. PubMed ID: 35793691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of Sex-Stratified Prediction Models for Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study.
    Albertsen IE; Søgaard M; Goldhaber SZ; Piazza G; Skjøth F; Overvad TF; Larsen TB; Nielsen PB
    Thromb Haemost; 2020 May; 120(5):805-814. PubMed ID: 32369851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment.
    Kooiman J; van Hagen N; Iglesias Del Sol A; Planken EV; Lip GY; van der Meer FJ; Cannegieter SC; Klok FA; Huisman MV
    PLoS One; 2015; 10(4):e0122520. PubMed ID: 25905638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.
    Senoo K; Proietti M; Lane DA; Lip GY
    Am J Med; 2016 Jun; 129(6):600-7. PubMed ID: 26482233
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
    Djulbegovic M; Lee AI; Chen K
    J Eval Clin Pract; 2020 Feb; 26(1):7-17. PubMed ID: 31190408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Associations between anticoagulant treatment pathways and self-reported harms in patients recently diagnosed with venous thromboembolism.
    Pan S; Allahwerdy F; Kim K; Feehan M; Jones AE; Munger MA; Witt DM
    Thromb Res; 2019 Oct; 182():95-100. PubMed ID: 31473404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bleeding Risk in Elderly Patients with Venous Thromboembolism Who Would Have Been Excluded from Anticoagulation Trials.
    Schenker C; Stalder O; Méan M; Tritschler T; Righini M; Rodondi N; Aujesky D
    Thromb Haemost; 2023 Apr; 123(4):427-437. PubMed ID: 36649737
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation of Bleeding Risk Prediction Scores for Patients With Major Bleeding on Direct Oral Anticoagulants.
    Tchen S; Ryba N; Patel V; Cavanaugh J; Sullivan JB
    Ann Pharmacother; 2020 Dec; 54(12):1175-1184. PubMed ID: 32517484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.